TODAY'S HEADLINES

FDA warns about popular diabetes drugs

In alarming news for patients taking two major medications, FDA is warning that interim safety results from an ongoing clinical trial found an increase in foot and leg amputations with the drugs. Read more

New treatment for kidney cancer gets OK

Find out why FDA's approval of a new treatment of advanced renal cell carcinoma is so important. Read more

CONTINUING PHARMACY EDUCATION

Keep your patients moving: An overview of treatment options for constipation

This month's CE activity, "Keep your patient moving: An overview of treatment options for constipation," is open for pharmacists and pharmacy technicians.
The goal of this program is to assist pharmacists and pharmacy technicians in their understanding of the role of linaclotide, lubiprostone, methylnaltrexone, and naloxegol in the treatment of constipation after conventional nonpharmacologic interventions and conventional laxatives such as bulking agents, osmotic laxatives, and stimulant laxatives have failed.
Pharmacists and pharmacy technicians can earn up to 2 hours of CPE credit for completing this knowledge-based activity from the University of Connecticut School of Pharmacy and Drug Topics. More

EDITOR'S PICK

National diabetes prevention program saves thousands

Find out how a diabetes prevention program—which will now go nationwide—helped patients lose 5% of their body weight and save thousands of dollars. Read more

May 27, 2016

National Managed Care Pharmacy Survey 2016

Your input is needed! Managed Healthcare Executive, in partnership with Access Market Intelligence and the National Institute of Collaborative Healthcare, is seeking your opinion on the current state of pharmacy. Take the survey and you could win a $200 Visa gift card. Answer Now.

Related Articles

FDA: Diabetes drugs don't need death warning

Opdivo snags two new cancer approvals